首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer
【24h】

Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer

机译:评价新型前列腺特异性膜抗原靶向近红外成像剂,用于前列腺癌的荧光引导手术

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: The ability to locate and remove all malignant lesions during radical prostatectomy leads not only to prevent biochemical recurrence (BCR) and possible side effects but also to improve the life expectancy of patients with prostate cancer. Fluorescence-guided surgery (FGS) has emerged as a technique that uses fluorescence to highlight cancerous cells and guide surgeons to resect tumors in real time. Thus, development of tumor-specific near-infrared (NIR) agents that target biomarkers solely expressed on prostate cancer cells will enable to assess negative tumor margins and affected lymph nodes.
机译:目的:在自由基前列腺切除术期间定位和去除所有恶性病变的能力不仅可以防止生物化学复发(BCR)和可能的副作用,而且还可以改善前列腺癌患者的预期寿命。 荧光引导的手术(FGS)作为一种使用荧光来突出癌细胞并实时切除肿瘤的外科医生的技术。 因此,靶近红外(NIR)近红外(NIR)试剂的发展,其仅在前列腺癌细胞上表达的生物标志物将能够评估阴性肿瘤余量和受影响的淋巴结。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号